Tag: Senza
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
High-frequency SCS takes the stage to relieve chronic pain from diabetic...
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...
Nevro receives TGA approval for Senza II spinal cord stimulation system...
The Therapeutic Goods Administration (TGA) has granted approval to Nevro for its next-generation Senza II spinal cord stimulation system delivering the company’s proprietary HF10...